Robert Hofmeister PhD

Dr. Hofmeister joined TCR2 in 2015 as the company’s first employee. He brings nearly two decades of scientific leadership and a successful track record of drug discovery and early development. Previously, Dr. Hofmeister was the Vice President of Immuno-Oncology at EMD Serono where he was involved in the development of now approved Bavencio (avelumab) and building the company’s immuno-oncology platform.

He started his biotech career at Micromet AG, now Amgen Research Munich, where he helped shape the development of Blincyto, the first FDA-approved bispecific antibody for the treatment of refractory ALL. Dr. Hofmeister received his Ph.D. from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute.